ABOUT ADVANCED ACCELERATOR APPLICATIONS
Advanced Accelerator Applications USA, Inc. (AAA), a Novartis company, is developing targeted radioligand therapies and precision imaging radioligands for oncology indications. We are committed to transforming patients’ lives by leading innovation in nuclear medicine. AAA has a legacy as a leader in radiopharmaceutical drugs for Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT) diagnostic imaging.
For more information, please visit: www.adacap.com.
Contact a representative:
Laran L. Hyder, MHA
Associate Director, US Patient Advocacy, NET & RST
This information is for educational purposes only and does not substitute for medical advice or constitute an endorsement by LACNETS. Talk to your medical team about your individual care and treatment.